CTLA4 and neoplasm: Various ICIs have been discovered to inhibit specific proteins (e.g., cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) [2] and programmed cell death protein 1 (PD-1) in tumor-immune environments and thereby eliminate tumor cells [3,4,5,6].